Related references
Note: Only part of the references are listed.Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naive study
Jason K. Sicklick et al.
GENOME MEDICINE (2021)
Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers
Sahana Somasegar et al.
GYNECOLOGIC ONCOLOGY (2021)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
V. Rodriguez-Freixinos et al.
GYNECOLOGIC ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
Aly-Khan A. Lalani et al.
EUROPEAN UROLOGY (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing
Yusuke Shibuya et al.
GENES CHROMOSOMES & CANCER (2018)
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing
Se Ik Kim et al.
GYNECOLOGIC ONCOLOGY (2018)
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2018)
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2018)
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Jennifer X. Ji et al.
JOURNAL OF PATHOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
Min Wang et al.
SCIENTIFIC REPORTS (2018)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management
Katsutoshi Oda et al.
GYNECOLOGIC ONCOLOGY (2018)
Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis
Yoshiaki Maru et al.
GYNECOLOGIC ONCOLOGY (2017)
Identification of molecular targets in vulvar cancers
Marguerite L. Palisoul et al.
GYNECOLOGIC ONCOLOGY (2017)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
Brooke E. Howitt et al.
ONCOIMMUNOLOGY (2017)
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks
Ryusuke Murakami et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Molecular Profiling of Clear Cell Ovarian Cancers Identifying Potential Treatment Targets for Clinical Trials
Michael L. Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies
Francesco Piva et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma
Nathaniel L. Jones et al.
GYNECOLOGIC ONCOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
Clear cell carcinoma of the ovary: A review of the literature
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy
C. Lance Cowey et al.
CURRENT ONCOLOGY REPORTS (2009)
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2008)
Prognostic implication of endometriosis in clear cell carcinoma of the ovary
J. P. Orezzoli et al.
GYNECOLOGIC ONCOLOGY (2008)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma
KQ Cai et al.
HUMAN PATHOLOGY (2004)
Share Paper
